WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SF 3155

Summary of SF 3155 – Amyotrophic lateral sclerosis research appropriation provision and appropriation cancellation provision

Overview

SF 3155 is a Minnesota Senate bill introduced on April 1, 2025 and referred to the Higher Education committee. The bill’s title indicates it would address two main areas: (1) an ALS (amyotrophic lateral sclerosis) research appropriation provision and (2) an appropriation cancellation provision. A companion bill is HF 2930.

Purpose and intent

  • The primary aim, as suggested by the title, is to establish or modify state appropriations related to ALS research.
  • It also appears to create or clarify a mechanism for canceling appropriations (i.e., an appropriation cancellation provision), potentially governing how previously allocated funds for ALS research or related activities could be rescinded or redirected.
  • The exact language, scope, and triggers for these provisions are not provided in the summary available.

Key provisions (as indicated by the title)

  • ALS research appropriation provision: Likely to authorize, specify, or adjust state funding directed toward ALS research. This may involve appropriations to higher education institutions, health-related agencies, or affiliated research programs (potentially including the University of Minnesota, given the bill’s subject areas).
  • Appropriation cancellation provision: Likely to establish procedures or criteria for canceling or repurposing appropriations, including timelines, oversight, or conditions under which funds can be rescinded.

Note: The exact dollar amounts, eligible recipients, eligible projects, reporting requirements, sunset provisions, or oversight mechanisms are not detailed in the provided information.

Affected entities and stakeholders

  • Higher Education sector in Minnesota, including universities and research programs.
  • Health and health-related departments or agencies.
  • The University of Minnesota (as a probable recipient or recipient-aware entity).
  • Researchers and programs focused on ALS.

Procedural and timeline aspects

  • Introduced and given first reading on April 1, 2025.
  • Referred to the Higher Education committee, indicating initial committee review and potential amendments before any floor action.
  • The companion bill HF 2930 may parallel or complement SF 3155’s provisions.

Related legislation

  • Companion: HF 2930 (House of Representatives)

Potential impacts and considerations

  • Could increase or reallocate state funding for ALS research and establish a formal process for rescinding such funds.
  • May influence budgeting and funding priorities within higher education and health sectors.
  • The effectiveness will depend on the exact statutory language, including eligibility, evaluation criteria, reporting requirements, and safeguards around appropriation cancellation.

Next steps for readers

  • Monitor SF 3155’s progression in the Higher Education committee for amendments, fiscal notes, and the bill text.
  • Compare with HF 2930 for alignment or differences in ALS research funding and appropriation cancellation provisions.
  • Watch for any fiscal impact statements or stakeholder testimony that clarifies recipients, eligible projects, and oversight mechanisms.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.